, C max and GD parameters G tot , R max , t Rmax were log-transformed prior to analysis using a mixed effects model.
Results:
There were no apparent differences between PK profiles at the 5-mm or 8-mm injection depth in either study, demonstrated by the ratios of geometric means of AUC 0-tlast , AUC 0-∞ , and C max being close to 1, with 90% confidence intervals (CI) within (0.80, 1.25). There were no apparent differences between GD profiles at either injection depth with the ratios of G tot and R max near unity and 90% CIs that included 1. In both studies, the t Rmax values were similar between injection depths, with a small median of pairwise differences and a 90% CI that included zero.
are often advised to use longer needles (≥8 mm) due to the clinical perception that insulin should be injected deep into the SC layer of tissue. Results from a study in which skin thickness and SC adipose layer thickness were measured in patients with diabetes across 3 body mass index (BMI) subgroups (<25, 25-29. 9 , and ≥30 kg/m 2 ) demonstrated that skin thickness varies minimally between differing demographics, averaging approximately 1.9-2.4 mm across injection sites, ages, races, BMI, and sex, and is rarely >3 mm at injection sites for insulin. 6 In an open label, randomized, crossover study comparing the metabolic control between 5-mm and 8-mm needle lengths for insulin injection in obese patients with type 1 or type 2 diabetes, the 5-mm needle was found to be similar to the 8-mm needle with respect to metabolic control. 7 Similarly, in a study comparing investigator-administered injections of 20-and 60-unit (U) equivalent volumes of preserved sterile insulin diluent using 5-mm versus 8-mm needles, results demonstrated that the 5-mm needle was similar to the 8-mm needle with respect to insulin diluent leakage postinjection in obese patients with type 1 or type 2 diabetes, and there were no observed differences between the 5-mm and 8-mm needle with respect to pain intensity, bleeding, or bruising at injections sites. 8 The use of needles shorter than 5 mm has been evaluated as well; an early study by Frid et al did not detect any significant differences in regular human insulin absorption between superficial and deep injections in the subcutaneous fat layer of either the abdominal wall or the thigh. 9 Consistently, research by Hirsch et al demonstrated equivalent glycemic control with 4-mm versus 5-mm or 8-mm needles in subjects with a BMI between 20-49 kg/m 2 . 10 The 4-mm needle was also found to be safe, less painful, better tolerated, and provided equivalent glycemic control in comparison to the longer 8-mm and 12.7-mm needles in a prospective, randomized, crossover trial comparing glycemic control in obese subjects. 11 In addition, a study evaluating the pharmacokinetic (PK) properties of insulin lispro using 4-, 6-, and 8-mm needles in healthy Japanese males demonstrated bioequivalence between the 4-and 6-mm needles. 12 Insulin lispro (Humalog ® ), a rapid-acting insulin analog, has been available for clinical use in the United States since 1996; 13 however, the effect of injection depth on the PK and glucodynamic (GD) profile of insulin lispro in normal weight and obese patients has not been previously described. The objective of these analyses was to compare the PK and GD of insulin lispro after administration of single doses at either a 5-mm or an 8-mm injection depth in both normal weight and obese healthy subjects.
Study Design and Methods

Study Design
Two separate open-label, randomized, 2-period, crossover, euglycemic clamp studies were conducted. Study 1 was conducted in healthy, normal weight subjects and study 2 in healthy, obese subjects. In both studies, subjects received single doses of insulin lispro (0.25 U/kg) on 2 different occasions, with a washout time between study periods that ranged from 3 to 20 days. Both studies were approved by local investigational review boards and were performed in compliance with the principles of Good Clinical Practice and in accordance with the Declaration of Helsinki.
In each study period, subjects were dosed with insulin lispro after an 8-hour fast and underwent a euglycemic clamp procedure. Insulin lispro doses were administered subcutaneously into alternate lower abdominal quadrants. Injections were administered at an approximately 90-degree angle into a raised skinfold for the 8-mm injection depth (31-gauge pen needles; Becton, Dickinson and Company, Durham, NC, USA), and without raising a skinfold for the 5-mm injection depth.
Subjects
Inclusion criteria required subjects to be overtly healthy males or females, as determined by medical history and physical examination. In study 1, subjects were required to be between 21-50 years of age (inclusive) and to have a BMI between 18.5-29.9 kg/m 2 (inclusive). In study 2, subjects were required to be between 21-60 years old (inclusive) and to have a BMI ≥30 kg/m 2 . Subjects in both studies were excluded if fasting venous blood glucose (plasma) was >108 mg/dL (6 mmol/L). All subjects provided written informed consent.
Sample Size
Minimum sample sizes of 12 completers in study 1 and 16 completers in study 2 provided at least 80% probability to demonstrate that the 90% CI for the ratio of geometric means of insulin AUC and C max between the 5-mm and the 8-mm injection depths was within the reference range of (0.75, 1.33). The sample size for study 1 assumed a ratio of the means of 1.05 and a 20% intrasubject coefficient of variation (CV) for the PK parameters, based on previous insulin lispro PK studies (Eli Lilly and Company, Data on File). As study 2 was completed after study 1, the sample size calculation for study 2 assumed an anticipated ratio of the means of 1.00 and a 26% intrasubject CV for the PK parameters.
Euglycemic Clamp Procedure
Euglycemia (determined by the subject's baseline on each respective study dosing day) was maintained using a glucose clamp procedure for up to approximately 6 hours after insulin lispro administration (defined as time 0). Glucose infusion rates (GIR) were adjusted to maintain euglycemia, and blood samples were drawn for determination of blood glucose and serum insulin lispro concentrations throughout the clamp. For both studies, the clamp was discontinued if the GIR was 0 for at least 30 minutes after the clamp had been underway for at least 4 hours. For each study period, subjects remained in the fasting state until after the glucose clamp procedure was completed.
In both studies, a 20% dextrose solution was administered during the clamp procedure. In study 1, the GIR was adjusted manually to maintain the blood glucose concentrations within ±5% of the predose target value, defined as 5 mg/dL below the mean of predose fasting blood glucose concentrations measured on the day of the glucose clamp. Glucose concentrations were measured every 5 to 30 minutes throughout the clamping procedure using an automated glucose analyzer (Yellow Springs Instruments 2300 STAT PLUS [YSI] analyzer; Yellow Springs, OH, USA), and GIR changes were recorded. In study 2, GIRs were adjusted automatically via a Biostator ® (Life Science Instruments; Elkhart, IN, USA) to maintain the blood glucose concentration at 5% below the baseline glucose concentration, defined as the mean of 3 predose fasting blood glucose concentrations measured on the day of the glucose clamp. A blood sample for blood glucose determination was taken at least every 30 minutes for Biostator calibration. Glucose concentrations and GIR changes were electronically recorded using the Biostator.
Sample Collection and Assay
In both studies, serial blood samples were collected predose and up to 6 hours after the administration of each insulin lispro dose (10, 20, 30, 45, 60, 90, 120, 180, 240, 300, and 360 minutes relative to dosing), for the determination of serum insulin (lispro) concentrations.
Serum concentrations of insulin lispro were measured by validated radioimmunoassay (RIA) methods, in which samples were pretreated with 20% polyethylene glycol (PEG) to remove any endogenous anti-insulin antibodies. In study 1, PEG-treated samples were combined with [125I]-labeled despentapeptide insulin (DPI) and DPI antiserum, the bound complex was precipitated, and 125I counts in the pellet were determined with a gamma counter. The concentration of insulin was determined by interpolation from a standard curve prepared from insulin lispro, with lower and upper limits of quantitation of 20.0 and 2500.0 pM, respectively. The interassay accuracy (% relative error) during validation ranged from 90.8% to 103.9% and the interassay precision (% relative standard deviation) during validation ranged from 2.0% to 9.6%. In study 2, a validated RIA method using a specific insulin lispro antiserum was used to measure free immunoreactive insulin lispro (IRI). PEG-treated serum samples were combined with [125I]-labeled insulin lispro and insulin lispro antiserum, and the bound complex was precipitated. 125I counts in the pellet were determined with a gamma counter. The concentration of insulin lispro was determined by interpolation from a standard curve prepared from insulin lispro. This assay was demonstrated to be specific for insulin lispro, without notable cross-reactivity to endogenous human insulin. The lower limit of quantification was 96 pM, and the upper limit of quantification was 1721 pM. The interassay accuracy (% relative error [% nominal -100]) during validation ranged from -4.8% to -0.5%, and the interassay precision (% coefficient variation) during validation ranged from 3.0% to 13.5%. For both studies, serum insulin concentration samples were assayed at MDS Pharma Services Saint Laurent, Quebec, Canada.
Pharmacokinetic and Glucodynamic Analyses
The PK and GD parameters estimated in both studies are described below. In both studies, PK parameters were evaluated by standard noncompartmental methods of PK analysis using PKS/WinNonlin Enterprise version 5.0. ), were also calculated. A locally weighted scatter plot smoothing (LOESS) function was applied to the individual raw data to obtain a fit from which the GD parameters were estimated.
Statistical Analysis
In both studies, PK parameters (AUC 
Safety
Safety was assessed via physical examination, vital signs, adverse event (AE) monitoring, and clinical laboratory evaluations. A follow-up visit was conducted within 14 days of the subject's last study drug dose.
Results
Demographics
Eighteen subjects entered study 1; 17 were randomly assigned to treatment, and 16 completed both treatment periods and were included in the PK evaluation. A total of 16 healthy subjects entered and completed study 2. Demographic characteristics for study 1 and study 2 are shown in Table 1 .
Pharmacokinetics
PK results for both studies are summarized in Table 2 , 1.25) . Similarly, no apparent differences were observed between the PK profiles of the 2 injection depths in study 2. In both studies, the statistical analysis of t max showed similar results for the 2 injection depths, with narrow 90% CI for median of pairwise differences that included zero.
Glucodynamics
GD results for study 1 and study 2 are summarized in Table 2 . Figure 1C and 1D shows the LOESS fits of GIR versus time profiles following the administration of 0.25 U/kg doses of insulin lispro via the 5-mm and 8-mm ) showed no evidence of a statistical difference between the 5-mm and 8-mm depths, and the statistical analysis of t Rmax demonstrated similar results for the 2 injection depths, with a small median of pairwise differences and a 90% CI that included zero. The late t Rmax50% had a median difference of 21 minutes and a narrow 90% CI.
Likewise, in study 2, there were no apparent differences between the GD profiles following administration of insulin lispro at either injection depth with the ratios (90% CI) of G for several subjects at the end of the clamp (6 subjects at the 5-mm injection depth and 10 subjects at the 8-mm injection depth); therefore it was not possible to calculate the late t Rmax50% in those cases.
Safety and Tolerability
There were no AEs related to study drug in either study as judged by the investigator. In both studies, the most commonly reported AEs were associated with the study procedures, such as bruises and swelling or pain over cannulation, venipuncture, and infusion sites. In study 1, 12 subjects reported a total of 20 AEs that were related to study procedures, and 1 subject reported an AE that was related to both the study procedure and the device used for injection. Of the AEs related to study procedures, 14 were mild, 5 were moderate, and 2 were considered severe (aching sensation and soreness at the glucose infusion site during the clamp procedure). In study 2, 5 subjects reported a total of 7 AEs, 2 of which were related to study procedures; all were considered mild in severity. There were no clinically significant alterations in laboratory values or vital signs in either study.
Discussion
There were no statistical differences in the PK or GD profiles of insulin lispro between the 5-mm or 8-mm injection depth in either study. A minor, not statistically significant trend for an increase in t Rmax was observed in both studies. Given there were no differences in t max between needle lengths, the reason for this trend is not known. In addition, the administration of insulin lispro at both injection depths appeared to be well tolerated in healthy subjects.
Taken together, these studies indicate that injection depths in the 5-to 8-mm range do not affect the PK or GD of insulin lispro in either population and provide further evidence to support the safety and efficacy of administration of insulin lispro at a 5-mm injection depth in obese patients with diabetes.
Since these studies were performed, new injection recommendations have been published advising the use of shorter needles (4-6 mm) for insulin injection. 5 More recent data in Japanese patients have showed no differences in glycemic control between 4-mm and 5-mm needles 14 and no differences in the exposure to insulin between 4-mm, 6-mm, and 8-mm needles. 13 Patients need to have their insulin reliably delivered into the SC tissue without discomfort, leakage, or injection site adverse effects. Needle lengths previously recommended for SC injection are now known to be too long for many adults and most children because of the increased risk of intramuscular (IM) injections. Needles of 5-mm and even 4-mm length are estimated to provide reliable subcutaneous drug delivery, with substantially reduced risk of IM injection. 6, 15 This is the first study comparing the PK and GD of insulin after administration of single doses at either a 5-mm or an 8-mm injection depth in both normal weight and obese healthy subjects using the euglycemic clamp procedure. The randomized crossover design was selected to allow comparison between injection depths on an intrasubject basis, allowing each subject to serve as his/her own control. The 0.25 U/ kg dose was selected, as it is a clinically relevant mealtime dose of insulin lispro for patients with either type 1 or type 2 diabetes. Healthy subjects were enrolled in these studies to minimize physiologic variability as well as other confounding factors, such as concomitant medications, commonly encountered in patient populations. While the use of healthy subjects could be considered a study limitation as they are not the target patient population, it does not impact the conclusion that the PK and GD profiles observed are similar for both injection depths. A direct comparison between the normal weight and obese populations was not performed, given the multiple differences between studies such as BMI inclusion criteria, clamp technique, injection device, insulin assays, geographic location, and population. A minor methodological limitation of these studies was that the actual depth of injection was not visualized (eg, with high frequency ultrasound).
Conclusion
In summary, there were no differences in PK or GD profiles for insulin lispro administered at a 5-mm or an 8-mm injection depth, in either a normal weight or an obese population. The data from these 2 studies support the use of shorter needles regardless of BMI and corroborate previous clinical data.
